In the wake of the previously emphasized role of HMGN1 in promoting anti‐tumor immunity with a preferential Th1‐polarizing ability, only in the past year have there been the first experimental results regarding the design of an HMGN1‐based vaccine as part of a combinational immunotherapy, proven effective in eradicating 60%–80% of three different melanin‐producing mouse melanomas.81, 82. This evidence concerns the gene HMGN1 and melanoma.